How much revenue did BIOLASE generate this year?
BIOLASE has achieved a revenue of 50.49 M USD this year.
BIOLASE Revenue 2024
BIOLASE Revenue
50.49 M USD
Ticker
BIOL
ISIN
US0909112072
WKN
894190
In 2024, BIOLASE's sales reached 50.49 M USD, a 2.7% difference from the 49.16 M USD sales recorded in the previous year.
The BIOLASE Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2025e | 54.01 | 30,97 |
| 2024e | 50.49 | 33,12 |
| 2023 | 49.16 | 34,02 |
| 2022 | 48.46 | 32,83 |
| 2021 | 39.19 | 42,18 |
| 2020 | 22.78 | 27,09 |
| 2019 | 37.8 | 37,80 |
| 2018 | 46.16 | 36,61 |
| 2017 | 46.93 | 32,24 |
| 2016 | 51.81 | 39,20 |
| 2015 | 48.48 | 32,16 |
| 2014 | 47.66 | 37,49 |
| 2013 | 56.43 | 37,37 |
| 2012 | 57.36 | 46,16 |
| 2011 | 48.86 | 43,63 |
| 2010 | 26.23 | 33,66 |
| 2009 | 43.35 | 46,27 |
| 2008 | 64.63 | 50,53 |
| 2007 | 66.89 | 51,62 |
| 2006 | 69.7 | 52,35 |
| 2005 | 61.98 | 49,90 |
| 2004 | 60.65 | 59,37 |
BIOLASE Revenue, EBIT, Net Income US0909112072 · 894190
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into BIOLASE, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by BIOLASE from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects BIOLASE’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of BIOLASE. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into BIOLASE’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing BIOLASE’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on BIOLASE’s growth potential.
BIOLASE Revenue, EBIT and net profit per share
| Date | BIOLASE Revenue | BIOLASE EBIT | BIOLASE Net Income |
|---|---|---|---|
| 2025e | 54.01 M undefined | -4.02 M undefined | -3.55 M undefined |
| 2024e | 50.49 M undefined | -8.58 M undefined | -16.43 M undefined |
| 2023 | 49.16 M undefined | -17.94 M undefined | -37.62 M undefined |
| 2022 | 48.46 M undefined | -25.34 M undefined | -28.85 M undefined |
| 2021 | 39.19 M undefined | -16.12 M undefined | -16.7 M undefined |
| 2020 | 22.78 M undefined | -18.54 M undefined | -34.21 M undefined |
| 2019 | 37.8 M undefined | -15.62 M undefined | -17.86 M undefined |
| 2018 | 46.16 M undefined | -18.2 M undefined | -21.52 M undefined |
| 2017 | 46.93 M undefined | -17.53 M undefined | -20.83 M undefined |
| 2016 | 51.81 M undefined | -14.96 M undefined | -17.56 M undefined |
| 2015 | 48.48 M undefined | -20.65 M undefined | -20.28 M undefined |
| 2014 | 47.66 M undefined | -17.94 M undefined | -18.93 M undefined |
| 2013 | 56.43 M undefined | -10.75 M undefined | -11.48 M undefined |
| 2012 | 57.36 M undefined | -2.53 M undefined | -3.06 M undefined |
| 2011 | 48.86 M undefined | -4 M undefined | -4.49 M undefined |
| 2010 | 26.23 M undefined | -11.46 M undefined | -12.02 M undefined |
| 2009 | 43.35 M undefined | -2.96 M undefined | -2.96 M undefined |
| 2008 | 64.63 M undefined | -6.96 M undefined | -9.13 M undefined |
| 2007 | 66.89 M undefined | -8.17 M undefined | -7.28 M undefined |
| 2006 | 69.7 M undefined | -4.49 M undefined | -4.69 M undefined |
| 2005 | 61.98 M undefined | -16.98 M undefined | -17.51 M undefined |
| 2004 | 60.65 M undefined | -2.17 M undefined | -23.21 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 60.65 M USD | -2.17 M USD | -23.21 M USD |
| 2005 | 61.98 M USD | -16.98 M USD | -17.51 M USD |
| 2006 | 69.7 M USD | -4.49 M USD | -4.69 M USD |
| 2007 | 66.89 M USD | -8.17 M USD | -7.28 M USD |
| 2008 | 64.63 M USD | -6.96 M USD | -9.13 M USD |
| 2009 | 43.35 M USD | -2.96 M USD | -2.96 M USD |
| 2010 | 26.23 M USD | -11.46 M USD | -12.02 M USD |
| 2011 | 48.86 M USD | -4 M USD | -4.49 M USD |
| 2012 | 57.36 M USD | -2.53 M USD | -3.06 M USD |
| 2013 | 56.43 M USD | -10.75 M USD | -11.48 M USD |
| 2014 | 47.66 M USD | -17.94 M USD | -18.93 M USD |
| 2015 | 48.48 M USD | -20.65 M USD | -20.28 M USD |
| 2016 | 51.81 M USD | -14.96 M USD | -17.56 M USD |
| 2017 | 46.93 M USD | -17.53 M USD | -20.83 M USD |
| 2018 | 46.16 M USD | -18.2 M USD | -21.52 M USD |
| 2019 | 37.8 M USD | -15.62 M USD | -17.86 M USD |
| 2020 | 22.78 M USD | -18.54 M USD | -34.21 M USD |
| 2021 | 39.19 M USD | -16.12 M USD | -16.7 M USD |
| 2022 | 48.46 M USD | -25.34 M USD | -28.85 M USD |
| 2023 | 49.16 M USD | -17.94 M USD | -37.62 M USD |
| 2024e | 50.49 M USD | -8.58 M USD | -16.43 M USD |
| 2025e | 54.01 M USD | -4.02 M USD | -3.55 M USD |
BIOLASE stock margins US0909112072 · 894190
The BIOLASE margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BIOLASE. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BIOLASE.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the BIOLASE's sales revenue. A higher gross margin percentage indicates that the BIOLASE retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the BIOLASE's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the BIOLASE's total revenue generated. When comparing the revenue margin year over year, investors can gauge the BIOLASE's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the BIOLASE. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the BIOLASE's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
BIOLASE Margin History
| BIOLASE Gross margin | BIOLASE Profit margin | BIOLASE EBIT margin | BIOLASE Profit margin |
|---|---|---|---|
| 2025e | 34.02 % | -7.43 % | -6.57 % |
| 2024e | 34.02 % | -16.99 % | -32.53 % |
| 2023 | 34.02 % | -36.48 % | -76.52 % |
| 2022 | 32.83 % | -52.29 % | -59.53 % |
| 2021 | 42.18 % | -41.13 % | -42.61 % |
| 2020 | 27.09 % | -81.39 % | -150.18 % |
| 2019 | 37.8 % | -41.32 % | -47.25 % |
| 2018 | 36.61 % | -39.43 % | -46.62 % |
| 2017 | 32.24 % | -37.35 % | -44.39 % |
| 2016 | 39.2 % | -28.87 % | -33.89 % |
| 2015 | 32.16 % | -42.59 % | -41.83 % |
| 2014 | 37.49 % | -37.64 % | -39.72 % |
| 2013 | 37.37 % | -19.05 % | -20.34 % |
| 2012 | 46.16 % | -4.41 % | -5.33 % |
| 2011 | 43.63 % | -8.19 % | -9.19 % |
| 2010 | 33.66 % | -43.69 % | -45.83 % |
| 2009 | 46.27 % | -6.83 % | -6.83 % |
| 2008 | 50.53 % | -10.77 % | -14.13 % |
| 2007 | 51.62 % | -12.21 % | -10.88 % |
| 2006 | 52.35 % | -6.44 % | -6.73 % |
| 2005 | 49.9 % | -27.4 % | -28.25 % |
| 2004 | 59.37 % | -3.58 % | -38.27 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 59.37 % | -3.58 % | -38.27 % |
| 2005 | 49.9 % | -27.4 % | -28.25 % |
| 2006 | 52.35 % | -6.44 % | -6.73 % |
| 2007 | 51.62 % | -12.21 % | -10.88 % |
| 2008 | 50.53 % | -10.77 % | -14.13 % |
| 2009 | 46.27 % | -6.83 % | -6.83 % |
| 2010 | 33.66 % | -43.69 % | -45.83 % |
| 2011 | 43.63 % | -8.19 % | -9.19 % |
| 2012 | 46.16 % | -4.41 % | -5.33 % |
| 2013 | 37.37 % | -19.05 % | -20.34 % |
| 2014 | 37.49 % | -37.64 % | -39.72 % |
| 2015 | 32.16 % | -42.59 % | -41.83 % |
| 2016 | 39.2 % | -28.87 % | -33.89 % |
| 2017 | 32.24 % | -37.35 % | -44.39 % |
| 2018 | 36.61 % | -39.43 % | -46.62 % |
| 2019 | 37.8 % | -41.32 % | -47.25 % |
| 2020 | 27.09 % | -81.39 % | -150.18 % |
| 2021 | 42.18 % | -41.13 % | -42.61 % |
| 2022 | 32.83 % | -52.29 % | -59.53 % |
| 2023 | 34.02 % | -36.48 % | -76.52 % |
| 2024e | 34.02 % | -16.99 % | -32.53 % |
| 2025e | 34.02 % | -7.43 % | -6.57 % |
BIOLASE Aktienanalyse
What does BIOLASE do?
BIOLASE Inc is a leading manufacturer of laser technology for dentistry and medical devices for ophthalmology. The company was founded in 1984 and has a wide range of innovative products used in dentistry. The history of BIOLASE began in the 1970s when a group of scientists and technicians at the University of California in Los Angeles started researching the use of lasers in dentistry. This research work led to the idea for BIOLASE, which was founded in 1984. The company set out to develop a new generation of tools for dental practice that work quickly and gently, minimizing the use of drills and other invasive instruments. BIOLASE's business model is based on the manufacture and sale of "laser systems" used in dentistry. These lasers are based on a technology that facilitates and improves the cutting process in dentistry and in the body itself. The devices use a combination of a specific wavelength of the laser itself and a precisely tuned water jet, which together enable higher precision and cutting accuracy. The company has several product lines designed for use in different areas of dentistry. One of BIOLASE's most important divisions is the manufacturing of dietary supplements. BIOLASE offers vitamins, minerals, and other dietary supplements specifically tailored to the needs of dentists and patients. These products are recommended by many dentists as they provide an effective way to improve the health of teeth and gums. One of BIOLASE's most well-known products is the Waterlase laser systems. These laser systems use a special laser solution that reduces the need for drills, thereby gently reducing pain and damage. There are a variety of applications for which these devices are used, including fillings, root canal treatments, jaw and implant surgery, and prophylactic instruments. BIOLASE lasers can also be used in other niches of ophthalmology, such as treating dry eyes. They are also used in the treatment of age-related eye diseases. The company has received several awards for its innovative products throughout its history, including the Edison Award for outstanding achievements in technology development. Overall, BIOLASE has established itself as an innovative provider of laser technology in dentistry and ophthalmology. The company's products are in high demand among dentists and ophthalmologists worldwide and contribute to optimizing and improving treatment methods in these areas. BIOLASE ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding BIOLASE's Sales Figures
The sales figures of BIOLASE originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing BIOLASE’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize BIOLASE's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in BIOLASE’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about BIOLASE stock
How much was the turnover of the company BIOLASE compared to the previous year?
The revenue of BIOLASE has increased by 2.7% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of BIOLASE?
The revenue of BIOLASE is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of BIOLASE measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of BIOLASE so important for investors?
The revenue of BIOLASE is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does BIOLASE pay?
Over the past 12 months, BIOLASE paid a dividend of 0.14 USD . This corresponds to a dividend yield of about 2,461.07 %. For the coming 12 months, BIOLASE is expected to pay a dividend of 0 USD.
What is the dividend yield of BIOLASE?
The current dividend yield of BIOLASE is 2,461.07 %.
When does BIOLASE pay dividends?
BIOLASE pays a quarterly dividend. This is distributed in the months of January, March, May, July.
How secure is the dividend of BIOLASE?
BIOLASE paid dividends every year for the past 0 years.
What is the dividend of BIOLASE?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is BIOLASE located?
BIOLASE is assigned to the 'Health' sector.
Wann musste ich die Aktien von BIOLASE kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of BIOLASE from 7/12/2005 amounting to 0.01 USD, you needed to have the stock in your portfolio before the ex-date on 6/24/2005.
When did BIOLASE pay the last dividend?
The last dividend was paid out on 7/12/2005.
What was the dividend of BIOLASE in the year 2023?
In the year 2023, BIOLASE distributed 0 USD as dividends.
In which currency does BIOLASE pay out the dividend?
The dividends of BIOLASE are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The BIOLASE stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von BIOLASE
Our stock analysis for BIOLASE Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BIOLASE Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
